Corona Remedies acquires 7 Bayer brands, ahead of IPO
In a strategic move signaling its growing ambitions, Corona Remedies has acquired seven well-established pharmaceutical brands from Bayer’s Indian portfolio. The acquisition, effective July 16, 2025, includes one cardiology product and six widely used brands in the women’s health and fertility space.




















